Human T-lymphotropic virus infection among blood donors in a national hospital of Lima City
Infección por virus T-linfotrópico humano en donantes de sangre en un hospital nacional de Lima
DOI:
https://doi.org/10.22258/hgh.2021.51.90Abstract
Introduction: human T-cell lymphotropic viruses (HTLV), particularly HTLV-1, are associated with adult T-cell leukemia/lymphoma (ATLL) and myelopathy/tropical spastic paraparesis (HAM / TSP). In South America, Peru is considered an endemic area.Objective: the aim of this study was to estimate the seroprevalence of HTLV 1-2 among blood donors in a national hospital of Lima City. Methods: Descriptive study based on a secondary source obtained from the blood bank of a peruvian hospital. The population was conformed by the blood donors both genders who applied in the period 2012 to 2015. The inclusion criteria were: having personal data, age, sex, blood group and the results of the screening test for HTLV-1 and HTLV-2. Out of 28249 admitted subjects, 28084 fulfilled the study criteria. Results: the mean age of the participants was 33, 5 years (SD = 10.02, min 17, max 70), the age groups of 20-29 and 30-39 were predominant, with 34.6% (n = 9727) and 30.9% (n = 8685) respectively. A 70.6% (n = 19825) was represented by males and 83.3% (n = 23407) had blood group O. The frequency of reactive results for HTLV 1-2 had an increasing trend from 0.6 % in 2012 to 1.4% in 2015. Considering the accumulated from the period 2012 to 2015, the frequency of reactive results was 1.1%. The reactive results were presented in greater proportion in males (p = 0.020) and in the age group of 30-39 years (p <0.001). Conclusions: the seroprevalence for HTLV in the applicants admitted as a blood donor was 1.1%. The reactive results were associated to the age group and the male sex. Keywords: Human T-lymphotropic virus, HTLV, Blood Donors, Prevalence, Peru (Source: MeSH, NLM).Downloads
References
Manns A, Blattner WA. The epidemiology of the human T-cell lymphotrophic virus type I and type II: etiologic role in human disease. Transfusion [Internet]. 1991; 31(1):67–75.
Coffin J. The discovery of HTLV-1, the first pathogenic human retrovirus. Proc Natl Acad Sci [Internet]. 2015;112(51):15525–15529.
Jogeda E-L, Avi R, Pauskar M, Kallas E, Karki T, Des Jarlais D, et al. Human T-lymphotropic virus types 1 and 2 are rare among intravenous drug users in Eastern Europe. Infect Genet Evol [Internet]. Elsevier B.V. 2016; 43:83–5.
Li X, Chen Y, Wu Z, Zhang N. Prevalence of human T-lymphotropic virus type 1 infection among blood donors in mainland China: a meta-analysis. Int J Infect Dis [Internet]. International Society for Infectious Diseases. 2014; 25:94–9.
Satake M, Iwanaga M, Sagara Y, Watanabe T, Okuma K, Hamaguchi I. Incidence of human T-lymphotropic virus 1 infection in adolescent and adult blood donors in Japan: a nationwide retrospective cohort analysis. Lancet Infect Dis [Internet]. Elsevier Ltd. 2016; 3099(16):1–9.
Gotuzzo E, Gonzáles E, Verdonck K, Mayer E. Veinte años de investigación sobre HTLV-1 y sus complicaciones médicas el Perú: perspectivas generales. Acta Med Per [Internet]. 2010; 27(3):196–203.
Gotuzzo E, Verdonck K, Gonzales E, Cabada M. Virus linfotrópico humano de células T tipo 1 (HTLV-1): una infección endémica en el Perú. Rev Peru Med Exp Salud Publica. 2004;21(4):253–61.
Ita F, Mayer EF, Verdonck K, Gonzalez E, Clark D, Gotuzzo E. Human T-lymphotropic virus type 1 infection is frequent in rural communities of the southern Andes of Peru. Int J Infect Dis [Internet]. International Society for Infectious Diseases. 2014;19(1):46–52.
Romaní F. Revisión sistemática de estudios epidemiológicos sobre la infección por el virus linfotrópico de células T humanas I/II en el Perú. Rev Peru Epidemiol. 2011;14(3).
Alarcón Villaverde J, Romaní Romaní F, Montano Torres S, Zunt JR. Transmisión vertical de HTLV-1 en el Perú. Rev Peru Med Exp Salud Publica. 2011;28(1):101–8.
Organización Panamericana de la Salud. Suministro de sangre para transfusiones en los países de Latinoamérica y del Caribe 2012 y 2013. Washington, D.C. 2015.
Organización Panamericana de la Salud. Suministro de sangre para transfusión en los países del Caribe y de Latinoamérica 2006, 2007, 2008 y 2009. Washington, D.C. 2010.
Organización Panamericana de la Salud. Suministro de sangre para transfusiones en los países del Caribe y de Latinoamérica en 2006 y 2007. Washington, D.C. USA; 2009.
Fuentes-Rivera J, Roca O. La experiencia de Perú con un programa nacional de bancos de sangre. Rev Panam Salud Publica. 2003;13(2/3):165–71.
Cabezas-Sánchez C. Enfermedades infecciosas desatendidas: un permanente reto para la salud pública y la equidad en el Perú. Rev Peru Med Exp Salud Publica [Internet]. 2014; 31(2):326-35.
Ministerio de Salud. Sistema de Gestión de la Calidad del Programa Nacional de Hemoterapia y Bancos de Sangre (PRONAHEBAS). NT No 011-MINSA/DGSP-V.01. Lima-Perú; 2004.
Moya J, Julcamanyan E. Seroprevalencia de marcadores infecciosos causantes de pérdidas de hemodonaciones en el Servicio de Banco de Sangre del Hospital Nacional Docente Madre Niño San Bartolomé de enero 2008 a diciembre del 2013. Horiz Med (Barcelona) [Internet]. 2014;14(4):6–14.
Salas P. Seroprevalencia de infecciones transmisibles por transfusión sanguínea. Hospital Nacional Arzobispo Loayza 2011-2014. Tesis para optar el título de especialista en patología clínica. Lima: Universidad San Martin de Porres; 2015.
Bermúdez-Forero MI, Berrío-Pérez M, Herrera-Hernández AM, Rodríguez-Rodríguez MJ, García-Blanco S, Orjuela-Falla G, et al. Prevalencia de la infección con el virus linfotrópico de células T humanas de tipo 1 y 2 en donantes de sangre en Colombia , 2001-2014: implicaciones sobre la seguridad de la transfusión. Biomédica. 2016;36(Supl. 2):194–200.
Bermúdez HC, Collazos JEM, Sierra MR, Fonseca AA. Seroprevalencia de tamizaje frente a virus linfotrópico de células T (HTLV) y factores asociados a coinfección en donantes voluntarios de sangre de Colombia. Salud Uninorte. 2014;30(2):95–103.
Macía C, Vargas S, Mora AM, Sarmiento AM, Pacheco R, Rosso F. Seroprevalencia del virus linfotrópico humano de tipos I y II en donantes del Banco de Sangre de la Fundación Valle del Lili , Cali, Colombia, 2008-2014. Biomédica. 2016;36(Supl. 2):108–15.
Dias-Bastos MR, Oliveira CDL, Carneiro-Proietti a. BF. Decline in prevalence and asymmetric distribution of human T cell lymphotropic virus 1 and 2 in blood donors, State of Minas Gerais, Brazil, 1993 to 2007. Rev Soc Bras Med Trop. 2010;43(6):615–619.
Viana GMDC, Nascimento M, De Oliveira R, Dos Santos A, Galvão C, Da Silva M. Seroprevalence of HTLV-1/2 among blood donors in the state of Maranhão, Brazil. Rev Bras Hematol Hemoter [Internet]. 2014;36(1):50–3.
Torres L, Fusilli E, Ramírez M, Sánchez C. Seroprevalencia de anticuerpos para el Virus Linfotrópico Humano HTLV I y II en muestras de donantes del Banco de Sangre de una clínica privada. Valencia, Venezuela. Informed. 2011;13(11):395–9.
Malan R, Berini C, Eirin M, Delfino C, Pedrozo W, Krupp R, et al. Seroprevalencia de HTLV-1/2 en donantes de sangre de la provincia de Misiones. Med (Buenos Aires). 2010;70(1):71–4.
San Martin H, Balanda M, Vergara N, Valenzuela M, Cartier L, Ayala S, et al. Human T-Lymphotropic Virus Type 1 and 2 Seroprevalence Among First-Time Blood Donors in Chile, 2011–2013. J Med Virol. 2016;88:1067–75.
Dodd R, Notari E, Nelson D, Foster G, Krysztof D, Kaidarova Z, et al. Development of a multisystem surveillance database for transfusion-transmitted infections among blood donors in the United States. Transfusion [Internet]. 2016; 56(11):2781–9.
Perú. Ministerio de Salud. Programa Nacional de Hemoterapia y Bancos de Sangre. Guía para promotores en donación voluntaria de sangre [Internet]. Perú. 2001.
Diarra AB, Kouriba B, Guindo A, Maiga AI, Diabaté DT, Douyon I, et al. Prevalence of HTLV-I virus in blood donors and transfusion in Mali: Implications for blood safety. Transfus Clin Biol [Internet]. 2014;21(3):139–42.
Trujillo L, Muñoz D, Gotuzzo E, Yi A, Watts D. Prácticas sexuales y seroprevalencia de infección por VIH, HTLV-1 y sífilis en meretrices clandestinas de Lima. Rev méd hered. 1996;7(4):162–71.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Juan Morales
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- The authors will retain their copyright and will guarantee to the journal right of first publication of their work, which will simultaneously be under a Creative Commons Attribution 4.0 License that allows third parties to share the work whenever attribuying their author and first publication in this journal.
- The Author is able to enter into separate, additional contractual arrangements for the nonexclusive distribution of the journal's published version of the Work (e.g., post it to an institutional repository or publish it in a book), as long as there is provided in the document an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post online a pre-publication manuscript (but not the Publisher’s final formatted PDF version of the Work) in institutional repositories or on their Websites prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).
![](<p><img src="https://www.redib.org/themes/lotura/images/logo.svg" alt="REDIB" /></p>){kind=logo}
![REDIB](<p><img%20src="https://www.redib.org/themes/lotura/images/logo.svg" alt="REDIB" /></p>){kind=logo}
![Ciencia Nueva hará parte del índice de Revistas en Consolidación de América Latina AmeliCA - Gestión de la Comunicación y la Promoción Institucional](<p><img%20src="https://comunicaciones.utp.edu.co/wp-content/uploads/sites/2/Melica-21-de-sep-2021.jpg" alt="Ciencia Nueva hará parte del índice de Revistas en Consolidación de América Latina AmeliCA - Gestión de la Comunicación y la Promoción Institucional" /></p>)
